Completion of £8.75 million Fundraising
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
13 October 2026
Verici Dx plc
(“Verici Dx” or the “Company”)
Completion of £8.75 million Fundraising
Restoration of Trading on AIM
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, has today announced that the Company has raised £8.75 million through the Placing announced on 8 October 2026 and the WRAP Retail Offer launched on 9 October 2026.
Following closing of the Fundraising, the Company is pleased to announce that the Capital Access Window has closed, and that trading of the Company’s Ordinary Shares on AIM will be restored with effect from 7:30am today.
Enquiries:
Verici Dx plc
Sara Barrington, CEO
Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets
(Nominated Adviser, Joint Broker & Joint Bookrunner)Tel: +44 (0)20 7496 3000
Russell Cook / Anastassiya Eley / Harry Littlewood
Oberon Capital
(Joint Broker & Joint Bookrunner)Tel: +44 (0)20 3179 0500
Mike Seabrook / Heena Karani
Walbrook PR
(Media & Investor Relations)Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Rachel Broad
Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk, to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure, from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDIOEFFEEFEEMSELS
